The approval is supported by data from the phase 3 VOLGA trial.
|Videos|October 21, 2020
Urologists share favorite pieces of advice from mentors
Author(s)Urology Times staff
In this video, 6 urologists each answer the question: What is the best piece of advice you've received from a mentor?
Advertisement
Anne M. Suskind, MD, MS; Lunan Ji, MD; Meredith R. Metcalf, MD; R. Casey O'Connor, MD; Kathleen Kieran, MD, MSc, MME; and Gabriela Ilie, PhD, all share advice they've received from mentors.
Advertisement
Related to this article
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
4
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
5